Los Angeles, CA14 Active Studies

Colorectal Cancer Clinical Trials in Los Angeles, CA

Find 14 actively recruiting colorectal cancer clinical trials in Los Angeles, CA. Connect with local research sites and explore new treatment options.

14
Active Trials
12
Sponsors
5,767
Enrolling

Recruiting Colorectal Cancer Studies in Los Angeles

RecruitingLos Angeles, CANCT06445062

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC...

1,130 participants
Revolution Medicines, Inc.
View Study Details
RecruitingLos Angeles, CANCT06662786

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (f...

1,000 participants
Janssen Research & Development, LLC
View Study Details
RecruitingLos Angeles, CANCT05855200

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective...

811 participants
GlaxoSmithKline
View Study Details
RecruitingLos Angeles, CANCT06750094

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with...

700 participants
Janssen Research & Development, LLC
View Study Details
RecruitingLos Angeles, CANCT06614192

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (I...

460 participants
AbbVie
View Study Details
RecruitingLos Angeles, CANCT06252649

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FO...

450 participants
Amgen
View Study Details
RecruitingLos Angeles, CANCT05673148

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limit...

364 participants
Alliance for Clinical Trials in Oncology
View Study Details
RecruitingLos Angeles, CANCT05382442

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who...

254 participants
Akeso
View Study Details
RecruitingLos Angeles, CANCT05379595

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when add...

225 participants
Janssen Research & Development, LLC
View Study Details
RecruitingLos Angeles, CANCT06792695

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC)....

120 participants
AstraZeneca
View Study Details
RecruitingLos Angeles, CANCT06937177

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy

This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed metastatic colorectal cancer. This st...

120 participants
Endevica Bio
View Study Details
RecruitingLos Angeles, CANCT06562543

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American an...

78 participants
Takeda
View Study Details
RecruitingLos Angeles, CANCT06730100

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

This phase II trial studies how well CBX-12 works in treating patients with microsatellite stable colorectal cancer that has spread to other parts of the body (metastatic) and is no longer responding ...

35 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLos Angeles, CANCT06634875

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be...

20 participants
Buzzard Pharmaceuticals
View Study Details

About Colorectal Cancer Clinical Trials in Los Angeles

Colorectal cancer starts in the colon or rectum and is the third most common cancer diagnosed in both men and women. Early detection through screening significantly improves outcomes. Treatments include surgery, chemotherapy, radiation, and targeted therapies.

There are currently 14 colorectal cancer clinical trials recruiting participants in Los Angeles, CA. These studies are seeking a combined 5,767 participants. Research is being sponsored by Revolution Medicines, Inc., Janssen Research & Development, LLC, GlaxoSmithKline and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Colorectal Cancer Clinical Trials in Los Angeles — FAQ

Are there colorectal cancer clinical trials in Los Angeles?

Yes, there are 14 colorectal cancer clinical trials currently recruiting in Los Angeles, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What colorectal cancer treatments are being tested?

The 14 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for colorectal cancer.

Data updated March 2, 2026 from ClinicalTrials.gov